T2DM patients with obesity commonly experience leptin resistance, and there is evidence of the therapeutic potential of leptin due to its glucoregulatory and antidiabetic actions based on clinical trial results [24]. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.